FDA Investigator Rose Xu
Rose Xu has inspections in 8 countries as of 19 Oct 2023. Rose Xu has collaborated with a combined 3066 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
16
Last Inspection Date:
19 Oct 2023
Investigator Role:
FDA Investigation Participant
Redica ID:
Country:
China,
Austria,
Spain,
United States of America,
Canada,
Brazil,
Portugal,
Germany
Co-Investigator(s):
Adam R Cooke,
Ademola O Daramola,
Alice S Tsao,
Amatul H Marium,
Amy L Singer,
Angela E Glenn,
Anita R Michael,
Ankur C Patel,
Anthony C Warchut,
Arthur T Ogdahl,
Azza Talaat,
Barbara Janine Breithaupt,
Barbara Jwilimczyk Macri,
Barbara M Frazier,
Bill Tacket, Jr,
Carl A Huffman, III,
Carl Lee,
Caroline H Le,
CDR Ileana Barreto Pettit,
CDR Thomas R Berry, PPh,
Charanjeet Jassal,
Cheryl A Clausen,
Christina Capacci Daniel, PhD,
Christopher T Middendorf,
Chryste D Best,
Cynthia Jim, CSO,
Cynthia T Cain,
Darren S Brown,
Daryl A Dewoskin,
Dell S Moller,
Denise M Digiulio,
Djamila Harouaka,
Dongping Dai, PhD,
Douglas G Ng,
Dr. Chunchang Fang,
Dr. Gang Wang, PhD,
Dr. Robert C Horan, MD,
Dr. Sriram Subramaniam, PhD,
Edwin Melendez,
Elizabeth D Gonzales,
Erika V Butler,
Frederick Razzaghi,
Gam S Zamil,
Gamal A Norton,
Gerardo Z Vazquez,
Ginger M Sykes,
Gretchen M Laws,
Gwyn G Dickinson,
Hang N Guo,
Harry J Brewer,
Heika R Tait,
Huiquan Wu,
Inga M Warr,
Iram R Hassan, PhD,
Isabel Y Espinosa,
James A Liubicich,
Jamie L Dion,
Jane L Chang,
Jared P Stevens,
Jawaid Hamid,
Jay T Wong,
Jean A Peeples,
Jennifer L Huntington,
Joanne E King,
Jonathan R Campos,
Jose Acruz Gonzalez,
Jose M Cayuela,
Junho Pak,
Justin A Boyd,
Kara D Dobbin,
Karen G Hirshfield,
Karen L Kosar,
Katherine Szestypalow,
Kathleen D Culver,
Kellia N Hicks,
Kevin D Kallander,
Kimberley A Hoefen,
Lata C Mathew, PhD,
Latorie S Jones,
LCDR Debra Emerson,
LCDR Michael H Tollon,
Libia M Lugo,
Liming Zhang,
Linda F Murphy,
Lindsey M Schwierjohann,
Lisa Sg Shelton,
Mabany Lizardi,
Marcus F Yambot,
Marea K Harmon,
Margaret M Sands,
Mark E Parmon,
Marvin D Jones,
Matthew B Casale,
Matthew R Dionne,
Melissa J Garcia,
Michael E Maselli,
Michael P Sheehan,
Michael R Goga,
Michelle D Haamid,
Michelle Haamid,
Mindy M Chou,
Miral B Patel,
Mizanne E Lewis,
Mra Davism,
Nadeem I Chaudhry,
Nebil A Oumer,
Neil J Bonzagni, PhD MPH,
Nicholas L Paulin,
Nicole E Knowlton,
Patricia D Stahnke,
Patrick C Klotzbuecher,
Paul L Bellamy,
Paul L Figarole, Jr,
Peter E Baker,
Peter S Diak,
Philip F Istafanos, DMV, MS,
Pratik S Upadhyay, DDC,
Qin Xu,
Rachael A Moliver,
Ramesh Sood,
Randy L Clarida,
Renee N Easter,
Robert C Coleman,
Robert C Steyert,
Robert J Ham,
Robert J Martin,
Robert M Barbosa,
Roger F Zabinski,
Ronald T Weber,
Rowena S Nguyen,
Roy C Stephens,
Russell J Glapion,
Saied A Asbagh,
Sandra A Hughes,
Sangeeta M Khurana, PhD,
Santiago Gallardo Johnson,
Satheesh Thomas,
Seneca D Toms,
Simone E Pitts,
Sonya M Edmonds,
Srinivas R Chennamaneni, PhD,
Srira Subramaniam, PhD,
Steven A Gonzales,
Steven C Madzo,
Susan O Oladeji,
Susan P Bruederle,
Susanna E Ford, Analyst,
Tajah L Blackburn,
Tamara L Setzer,
Tamil Arasu, PhD,
Tara K Carmody,
Tara K Normandin,
Theressa B Smith,
Tiki J Dixon,
Timothy T Kapsala,
Tracey L Harris,
Ucheabuchi C Chudi Nwankwor,
Uduak M Inokon,
Unnee Ranjan,
Vincent Thomas,
Vivin George,
Wayne D Mcgrath,
Wendy G Tan, PhD,
Xiomara Copeland,
Ying Zhang,
Yumi J Hiramine,
Yvesna C Blaise,
Zachary A Bogorad,
Zachary L Stamm,
Zakaria I Ganiyu,
Zakaria Wahba,
Zi Qiang Gu
Rose Xu's Documents
Publish Date | Document Type | Title |
---|---|---|
January, 2020 | EIR | Patheon Austria GmbH & CoKG - EIR, 2020-01-31 |
March, 2019 | FDA 483 | Catalent Pharma Solutions, LLC - Form 483, 2019-03-04 |
April, 2016 | FDA 483 | HIKMA FARMACEUTICA (PORTUGAL), S.A - Form 483, 2016-04-12 |
April, 2018 | FDA 483 | Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (FDF Site) - Form 483, 2018-04-03 |
February, 2014 | FDA 483 | TOLMAR INC - Form 483, 2014-02-12 |
May, 2017 | EIR | Bausch & Lomb Incorporated - EIR, 2017-05-26 |
February, 2015 | FDA 483 | CMIC CMO USA CORP - Form 483, 2015-02-13 |
May, 2017 | FDA 483 | Bausch & Lomb Incorporated - Form 483, 2017-05-26 |
February, 2015 | FDA 483 Response | CMIC CMO USA CORP - Form 483R, 2015-03-06 |
January, 2019 | FDA 483 | Amneal Pharmaceuticals of New York, LLC - Form 483, 2019-01-30 |
March, 2019 | EIR | Catalent Pharma Solutions, LLC - EIR, 2019-03-04 |
February, 2024 | FDA 483 | Baxter Pharmaceutical Solutions LLC - Form 483, 2024-02-20 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more